Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Issued Date
2022-09-16
Resource Type
ISSN
0264410X
eISSN
18732518
Scopus ID
2-s2.0-85136706967
Pubmed ID
36031500
Journal Title
Vaccine
Volume
40
Issue
39
Start Page
5657
End Page
5663
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine Vol.40 No.39 (2022) , 5657-5663
Suggested Citation
Kanokudom S., Assawakosri S., Suntronwong N., Chansaenroj J., Auphimai C., Nilyanimit P., Vichaiwattana P., Thongmee T., Yorsaeng R., Duangchinda T., Chantima W., Pakchotanon P., Srimuan D., Thatsanatorn T., Klinfueng S., Mongkolsapaya J., Sudhinaraset N., Wanlapakorn N., Honsawek S., Poovorawan Y. Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine Vol.40 No.39 (2022) , 5657-5663. 5663. doi:10.1016/j.vaccine.2022.08.033 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83605
Title
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Other Contributor(s)
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The present study compared the reactogenicity and immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results showed that headache, joint pain, and diarrhea were more frequent in the 15 μg- than the 30 μg-BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 μg- than the 50 μg-mRNA-1273 groups. No significant differences in immunogenicity were detected. These findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose. The reduced dose could be used to increase vaccine coverage in situations of limited global vaccine supply.